Rongrui Biotech Secures Nearly RMB 100 Million in Pre-A Funding to Accelerate Commercialization of Synthetic Biology Products

Recently,Zhejiang Rongrui Technology Co., Ltd.（(hereinafter referred to as)“Rongrui Technology” or the “Company”) completed nearly RMB 100 millionPre-Around of financing, led by Puhua Capital and CDHVGC(Innovation and Growth Fund) co-led the investment, with WinX Capital serving as the exclusive financial advisor.The funds raised in this round of financing will be primarily used to accelerate the development of the company's product pipeline, as well as to continuously advance industrialization and commercialization efforts.

Zhejiang Rongrui Technology Co., Ltd. was established in 2022. Leveraging technologies such as synthetic biology, the company focuses on the broad, high-value-added, and high-growth-potential application markets within the broader health sector, including raw materials for health supplements and high-value chemicals. By targeting both “hard substitution” and “incremental markets,” and driven by technological innovation, the company achieves reduced product costs and enhanced product quality, thereby meeting people’s demand for healthy living.

The company’s management team boasts over three decades of profound expertise in relevant fields and has established multiple collaborations with leading enterprises in niche sectors. The company has garnered high acclaim and widespread recognition from the industry for its forward-looking strategic layout, efficient R&D iteration and commercialization capabilities, as well as its commitment to scalability and cost control.

Rongrui TechnologyCEOMeng YanStatement: We extend our sincere gratitude to the investors in this funding round for their recognition and support of Rongrui, and we also thank all existing shareholders for their trust and assistance. The Company will further strengthen technological breakthroughs, improve production facility infrastructure, and establish a commercial channel system, thereby providing strong guarantees for sustained future performance growth and contributing to China’s advancement in biomanufacturing.

Puhua CapitalDirector Qiu WenyiStatement: The Rongrui team possesses extensive industrialization experience and a solid R&D foundation. Starting with high-demand health supplement ingredients, the company has been progressively enhancing its product portfolio and production capacity. We are optimistic about teams with comprehensive capabilities in R&D, production, sales, and operational management, and we hope that Rongrui will achieve rapid growth with the support of this round of financing.

CDH InvestmentsVGCSenior Partner Gao JieliangThe company has been deeply engaged in the field of synthetic biology for over three decades, achieving multiple breakthroughs in R&D and industrialization, which have earned widespread recognition within the industry. We are firmly optimistic about the company’s development prospects. Leveraging its robust technology platform, the company has established extensive layouts across various sectors, including food and high-value chemicals, thereby creating significant social value.

Xu Tong, Head of Bio-Manufacturing at WinX CapitalWinX Capital stated: “We extend our sincere gratitude to Zhejiang Rongrui Technology Co., Ltd. for its trust in WinX Capital, and to both new and existing shareholders for their strong support. It is our honor to have facilitated the company’s completion of this financing round. We believe that, leveraging its keen market insights, efficient technological iteration capabilities, and outstanding industrialization and commercialization acumen, the company will become a significant force in the field of biomanufacturing.”

Puhua Capital, founded in 2004 and headquartered in Hangzhou, maintains offices in Beijing, Shanghai, Shenzhen, and London, UK. The firm focuses on investments in four key sectors: frontier technology, new energy and advanced materials, healthcare, and consumer culture. Leveraging its deep industry insights and extensive capital market experience, Puhua Capital has established a “capital + industry” dual-drive strategy, committed to investing early, innovatively, specially, and in growth-stage companies, serving as an incubator and accelerator for entrepreneurship and innovation. Currently, the firm manages assets exceeding RMB 27 billion, having continuously supported the development of nearly 500 startups, with over 150 achieving exits through IPOs and other channels.

CDH VGC is a fund under CDH Investments, specializing in innovation and growth investments. It combines the innovative vision of venture capital (VC) with the professional rigor of growth investing. Since its establishment, CDH VGC has adhered to CDH Investments’ core philosophy of partnering with strivers to create long-term value. Committed to addressing societal pain points, the fund helps enterprises improve efficiency and reduce costs through technological or business model innovation, and has systematically invested in over 100 innovative companies with significant industry influence. CDH VGC firmly believes that allocating resources to outstanding innovative growth enterprises will inevitably drive progress in both industry and society.

WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in Healthcare for 2024,” First New Voice’s “No. 1 Financial Advisory Firm in Healthcare for 2022–2024,” and VCBeat’s “Annual Healthcare Financial Advisor” as part of the “Future Healthcare 100” list for 2022–2024.